Dabur Pharma has said that it has got approval from the Drug Controller General of India (DCGI) for its anti-cancer drug delivery formulation 'Nanoxel' (nanoparticle paclitaxel) as an indication for three more types of cancer. Nanoxel is a new anti-cancer drug delivery system developed by Dabur Pharma, which allows more targeted treatment and avoid side effects of Chemotherapy. The company informed the stock exchanges that its proprietary Nanoxel has been approved by DGCI for treatment of ovarian Cancer, non-small cell lung cancer and also for AIDS related Kaposis' Sarcoma (abnormal growth of tissues under the skin). "This approval will help a much larger patient population have access to significantly safer and more convenient therapeutic alternative to conventional Paclitaxel," Dabur Pharma CEO Ajay Kumar Vij said in a statement.
Every time an offender stealthily leaves India to take refuge in another country, the Government of India starts all over again with its strategy of bringing him back to the nation to make him stan More
Helplinelaw can set up your session with quality and experienced lawyers to discuss and resolve your legal matters. You can avail consultation in form of sending questions, phone call or webchat discussion More